Meeting
2021 Genitourinary Cancers Symposium
High-risk nonmetastatic prostate cancer in the elderly: Does adjuvant chemotherapy affect survival?
Authors
Komal Akhtar
SUNY Upstate Medical University, Syracuse, NY
Komal Akhtar , Margaret K Formica , Bhaskara Madhira , Alina Basnet
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Localized Disease
Track
Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 229)
DOI
10.1200/JCO.2021.39.6_suppl.229
Abstract #
229
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Cost-effectiveness of abiraterone acetate for high-risk nnon-metastatic prostate cancer.
First Author: Nataniel Hernan Lester-Coll
Poster
2019 Genitourinary Cancers Symposium
Overall survival outcomes with the use of adjuvant chemotherapy, radiation therapy and hormone therapy in high-risk, very-high-risk and node-positive prostate cancer post radical prostatectomy: A NCDB analysis.
First Author: Alina Basnet
Poster
2019 Gastrointestinal Cancers Symposium
Adjuvant therapy is associated with improved survival in pT1N1 gastric cancer in a heterogeneous western patient population.
First Author: Matthew R. Porembka
Poster
2018 Genitourinary Cancers Symposium
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303).
First Author: Scott Williams